Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SVRA Savara Inc

Pre-Market Trading 01-10 06:28:35 EST

3.04

-0.01

-0.33%

High3.13	Low3.02	Vol574.64K
Open3.05	D1 Closing3.05	Amplitude3.44%
Mkt Cap521.72M	Tradable Cap316.16M	Total Shares171.62M
T/O1.76M	T/O Rate0.55%	Tradable Shares104.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SVRA","market":"US","secType":"STK","nameCN":"Savara Inc","latestPrice":3.04,"timestamp":1736370000000,"preClose":3.05,"halted":0,"volume":574641,"delay":0,"floatShares":104000000,"shares":171618944,"eps":-0.425487,"marketStatus":"Pre-Market Trading","change":-0.01,"latestTime":"01-10 06:28:35 EST","open":3.05,"high":3.125,"low":3.02,"amount":1757747.3461497,"amplitude":0.034426,"askPrice":3.47,"askSize":100,"bidPrice":1.83,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.425487,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1736519400000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.04,"postHourTrading":{"tag":"盘后","latestPrice":3.04,"preClose":3.04,"latestTime":"17:25 EST","volume":11359,"amount":34531.36,"timestamp":1736375136653},"volumeRatio":0.8998351099408401,"impliedVol":5.1271,"impliedVolPercentile":1},"requestUrl":"/m/hq/s/SVRA/tweets","defaultTab":"tweets","newsList":[{"id":"2495584767","title":"Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company","url":"https://stock-news.laohu8.com/highlight/detail?id=2495584767","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495584767?lang=en_us&edition=fundamental","pubTime":"2024-12-29 22:54","pubTimestamp":1735484061,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Savara's stock price might be vulnerable to their trading decisions. A total of 10 investors have a majority stake in the company with 51% ownership. If you want to know who really controls Savara Inc. , then you'll have to look at the makeup of its share registry. With 53% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .Let's delve deeper into each type of owner of Savara, beginning with the chart below.What Does The Institutional Ownership Tell Us About Savara?NasdaqGS:SVRA Earnings and Revenue Growth December 29th 2024. While the precise definition of an insider can be subjective, almost everyone considers board membe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-inc-nasdaq-svra-largely-145421624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","QLD","QID","BK4112","IE00B64PRP62.GBP","BK4585","IE00BGHQF748.EUR","USJW.SI","USAW.SI",".IXIC","IE00B3QW5Z07.USD","LU2095319765.USD","NQmain","PSQ","IE00BKPKM429.USD","NVIW.SI","BK4588","TQQQ","SVRA","SQQQ","LU2210149790.SGD","BK4139","LU2210150020.SGD","TSYW.SI","NDAQ"],"gpt_icon":1},{"id":"2492144582","title":"Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2492144582","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492144582?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:33","pubTimestamp":1734701604,"startTime":"0","endTime":"0","summary":"Savara (SVRA) has an average rating of Buy and mean price target of $9.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2492044303","title":"Savara Initiated at Overweight by Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2492044303","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492044303?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:33","pubTimestamp":1734701580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 08:33 ET (13:33 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2492150936","title":"Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2492150936","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492150936?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:07","pubTimestamp":1734559624,"startTime":"0","endTime":"0","summary":"Savara  said late Wednesday it started a rolling submission of a biologics license application, or BLA, to the US Food and Drug Administration for Molbreevi, aimed at potentially treating autoimmune Pulmonary Alveolar Proteinosis, a rare lung disease.The clinical-stage biopharmaceutical company said it plans to finalize the BLA submission by the end of Q1 2025 and intends to seek priority review.Shares of Savara were up 0.3% in after-hours trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2492398152","title":"BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492398152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492398152?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:28","pubTimestamp":1734557306,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Initiates Rolling Submission Of A Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For Molbreevi* For The Potential Treatment Of Autoimmune Pulmonary Alv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492541671","title":"Savara initiates rolling submission of BLA to FDA for MOLBREEVI","url":"https://stock-news.laohu8.com/highlight/detail?id=2492541671","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492541671?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:10","pubTimestamp":1734556238,"startTime":"0","endTime":"0","summary":"Savara (SVRA) initiated a rolling submission of a Biologics License Application to the FDA for MOLBREEVI for the potential treatment of aPAP, a chr...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/savara-initiates-rolling-submission-of-bla-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/savara-initiates-rolling-submission-of-bla-to-fda-for-molbreevi?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154870","title":"Savara Inc - Expects to Complete Bla Submission by End of 1Q 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154870","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154870?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154804","title":"Savara Initiates Rolling Submission of a Biologics License Application (Bla) to the U.S. Food and Drug Administration (FDA) for Molbreevi* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Apap)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154804?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2492154389","title":"Savara Inc - to Request Priority Review of Bla","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154389","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154389?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA9QXFWM:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SVRA"],"gpt_icon":0},{"id":"2492154924","title":"Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154924","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154924?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:05","pubTimestamp":1734555900,"startTime":"0","endTime":"0","summary":"-- Company Expects to Complete BLA Submission by End of 1Q 2025 --. LANGHORNE, Pa., December 18, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, initiated a rolling submission of a BLA to the FDA for MOLBREEVI for the potential treatment of aPAP, a chronic and debilitating rare lung disease characterized by the abnormal build-up of surfactant in the alveoli of the lungs.MOLBREEVI was granted Fast Track and Breakthrough Therapy Designations in 2019 for the treatment of patients with aPAP. As a result, the Company is allowed to submit individual modules of the BLA as they are completed rather than waiting to submit the application once all modules are available. The Company will request a priority review of the BLA when the submission is completed.Savara is a clinical stage biopharmaceutical company focused on rare respiratory dis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vplXTWW2XCRclXdx7kD6Pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0fdc83e864569eab3eb62672bd52d294","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vplXTWW2XCRclXdx7kD6Pw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/0fdc83e864569eab3eb62672bd52d294"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-initiates-rolling-submission-biologics-210500382.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4136","LU2463526074.USD","SVRA","IP","BK4585","PIM","BK4139","BK4588"],"gpt_icon":0},{"id":"2492918162","title":"Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2492918162","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492918162?lang=en_us&edition=fundamental","pubTime":"2024-12-18 05:05","pubTimestamp":1734469500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., December 17, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the Company will present and host 1x1 meetings at the 43rd Annual J.P. Morgan Healthcare Conference.Date/Time of Presentation: January 15, 5:15pm PT/8:15pm ETPresenter: Matt Pauls, Chair and Chief Executive Officer, SavaraLocation: Westin St. Francis, San Francisco, Elizabethan C Room. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/t4YEaegyrOthupdwm_Qbmg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6d5f8bd19baaf939f45628ae62d994a0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/t4YEaegyrOthupdwm_Qbmg--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6d5f8bd19baaf939f45628ae62d994a0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-43rd-annual-210500051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1162221912.USD","BK4127","SVRA","LU1989772840.SGD","BK4504","LU1548497426.USD","LU1720051017.SGD","LU2357305700.SGD","HCSG","LU0320765646.SGD","BK4137","LU1989772923.USD","LU2028103732.USD","BK4516","BK4581","BK4139","LU0106261372.USD","BK4534","LU0098860793.USD","LU0006306889.USD","LU1363072403.SGD","LU2023251221.USD","LU2089283258.USD","BK4585","LU2271345857.HKD","LU0225283273.USD","LU1720051108.HKD","IE00BZ1G4Q59.USD","LU0314104364.USD","LU0158827948.USD","LU0971096721.USD","IE00BKVL7J92.USD","LU1074936037.SGD","LU2089284900.SGD","LU0267386448.USD","LU1668664300.SGD","LU2111349929.HKD","LU0158827781.USD","LU0106831901.USD","BK4588"],"gpt_icon":0},{"id":"2485890214","title":"Savara Announces New Employment Inducement Grant","url":"https://stock-news.laohu8.com/highlight/detail?id=2485890214","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485890214?lang=en_us&edition=fundamental","pubTime":"2024-11-23 05:05","pubTimestamp":1732309500,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc. , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to four new employees.On November 20, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to four new employees who recently joined the Company. The inducement awards consist of options to purchase an aggregate of 80,000 shares of the Company’s common stock and restricted stock units  covering an aggregate of 70,000 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635 of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SQxpFOkTqEha3yLTkr6olA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f5fd24ccdfc385687a9b19729c0e9901"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-employment-inducement-grant-210500143.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SVRA","SQQQ","NQmain","TQQQ",".IXIC","QLD","MNQmain","PSQ","QID"],"gpt_icon":1},{"id":"2485263865","title":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) At The British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485263865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485263865?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:36","pubTimestamp":1732282613,"startTime":"0","endTime":"0","summary":"BRIEF-Savara Announces Encore Presentation Of Results From The Phase 3 Impala-2 Trial Of Molgramostim Inhalation Solution (Molgramostim) In Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2485250364","title":"Savara Announces Encore Presentation of Results From the Phase 3 Impala-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250364?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241122:nTUA2PPCPL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2485250136","title":"Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485250136","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485250136?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:05","pubTimestamp":1732280700,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 22, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that an encore presentation of results from the pivotal, Phase 3 IMPALA-2 trial will be presented at the British Thoracic Society  Winter Meeting, taking place November 27-29, 2024, in London, England.About Savara Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim inhalation solution , is a recombinant human granulocyte-macrophage colony-stimulating factor  in Phase 3 development for autoimmune pulmonary alveolar proteinosis . Molgramostim is delivered via an investigational eFlow Nebulizer System  specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More informa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vF9H6VvKk8gOMnTen3ZuBQ--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a5c0f506c1f293b824bb9ee664d4ee81"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-encore-presentation-results-130500452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","BK4139"],"gpt_icon":0},{"id":"2483560728","title":"Savara Shares Fall After Evercore ISI Downgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2483560728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483560728?lang=en_us&edition=fundamental","pubTime":"2024-11-14 03:19","pubTimestamp":1731525549,"startTime":"0","endTime":"0","summary":"Savara  shares were down over 14% in recent Wednesday trading after Evercore ISI downgraded the company's stock to in line from outperform and cut its price target to $5 from $7.Trading volume stood at about 2.3 million shares against a daily average of roughly 1.2 million.Price: 3.29, Change: -0.54, Percent Change: -14.18","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2483853880","title":"Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483853880","media":"GuruFocus.com","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483853880?lang=en_us&edition=fundamental","pubTime":"2024-11-14 02:21","pubTimestamp":1731522086,"startTime":"0","endTime":"0","summary":"Evercore ISI downgraded Savara  to \"in line\" from \"outperform,\" citing worries over Molbreevi's FDA approval.The downgrading highlights possible obstacles in Savara's strategy to bring the medication to market resulting from doubts about the company's manufacturing capacity.Evercore also lowered Savara's price target to $5 from $7; SVRA stock is down 9.5% to open Wednesday's trading at $3.45. Analyst Liisa Bayko clarified that although Savara wants to finish its rolling Biologics License Application for Molbreevi by the end of the first quarter in 2025, its current manufacturing approach may hinder FDA clearance path. Should accepted with a priority evaluation, Molbreevi might enter the market by the end of 2025, possibly bringing in more than $500 million yearly, Bayko said.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/slb6hco9s4qvtSd.Xyb6oQ--~B/aD0zNjQ4O3c9NTQ3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/ac90e83fbe2c24857411d69cfbec7675","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/slb6hco9s4qvtSd.Xyb6oQ--~B/aD0zNjQ4O3c9NTQ3MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/ac90e83fbe2c24857411d69cfbec7675"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/evercore-downgrades-savara-manufacturing-concerns-182126627.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA"],"gpt_icon":0},{"id":"2483884981","title":"Savara Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2483884981","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483884981?lang=en_us&edition=fundamental","pubTime":"2024-11-13 22:53","pubTimestamp":1731509580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SVRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2024 09:53 ET (14:53 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA"],"gpt_icon":0},{"id":"2483785889","title":"Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2483785889","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483785889?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:06","pubTimestamp":1731503191,"startTime":"0","endTime":"0","summary":"Evercore ISI Downgrades Savara to In Line From Outperform, Adjusts Price Target to $5 From $7","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SVRA"],"gpt_icon":0},{"id":"2483000473","title":"Savara Announces Participation in Upcoming Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2483000473","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483000473?lang=en_us&edition=fundamental","pubTime":"2024-11-13 21:05","pubTimestamp":1731503100,"startTime":"0","endTime":"0","summary":"LANGHORNE, Pa., November 13, 2024----Savara Inc.  , a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of its management team will be attending the below listed upcoming healthcare conferences and participating in fireside chats.Jefferies London Healthcare Conference, November 19-21, 2024Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT. Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024Fireside Chat: December 3rd, 8:30am ET/5:30am PT. *MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.Media and Investor Relations Contact Savara Inc.Temre Johnson, Executive Director, Corporate Affairsir@savarapharma.com","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5VH9t4y.N6VaRwrQVEUalA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/605644126191325ff02841b3c85bbce0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5VH9t4y.N6VaRwrQVEUalA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/605644126191325ff02841b3c85bbce0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/savara-announces-participation-upcoming-healthcare-130500395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SVRA","BK4137","HCSG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.savarapharma.com;www.masttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0098},{"period":"1month","weight":-0.1461},{"period":"3month","weight":-0.1556},{"period":"6month","weight":-0.3783},{"period":"1year","weight":-0.2897},{"period":"ytd","weight":-0.0098}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.130484},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.048875},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.022561},{"month":4,"riseRate":0.583333,"avgChangeRate":0.025179},{"month":5,"riseRate":0.75,"avgChangeRate":0.049473},{"month":6,"riseRate":0.5,"avgChangeRate":-0.036588},{"month":7,"riseRate":0.416667,"avgChangeRate":-0.037047},{"month":8,"riseRate":0.5,"avgChangeRate":-0.004589},{"month":9,"riseRate":0.5,"avgChangeRate":0.004673},{"month":10,"riseRate":0.083333,"avgChangeRate":-0.1617},{"month":11,"riseRate":0.5,"avgChangeRate":0.099362},{"month":12,"riseRate":0.583333,"avgChangeRate":0.241594}],"exchange":"NASDAQ","name":"Savara Inc","nameEN":"Savara Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Savara Inc,SVRA,Savara Inc股票,Savara Inc股票老虎,Savara Inc股票老虎国际,Savara Inc行情,Savara Inc股票行情,Savara Inc股价,Savara Inc股市,Savara Inc股票价格,Savara Inc股票交易,Savara Inc股票购买,Savara Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Savara Inc(SVRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Savara Inc(SVRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction